PLUS THERAPEUTICS, INC. (PSTV) Latest Filing Signal
Cross-checked across multiple AI analysts and grounded in the latest SEC filing.
powered by: earningsVibe.ai
Question:
What is the latest filing signal for PLUS THERAPEUTICS, INC.?
Answer:
Based on earningsVibe SuperAnalyst™ synthesis of the latest
10-K, PLUS THERAPEUTICS, INC.'s filing signal
turned negative.
earningsVibe SuperAnalyst™ Verdict:
TURNED NEGATIVE
Signal Performance — Stock Price Since Filing
30-Day Change
-33.79%
from filing date
60-Day Change
Pending
from filing date
Underlying analyst views from Perplexity, Gemini, Claude, and ChatGPT
PERPLEXITY
Continuing Negative
GEMINI
Turned Negative
CLAUDE
Turned Negative
CHATGPT
Continuing Negative
Unlock the Full Filing Analysis
See full earningsSig™ and risksSig™ analysis across 5,000+ companies
Get Started Free →No credit card required
Question:
What does PLUS THERAPEUTICS, INC. actually do?
Answer:
Plus Therapeutics is a U.S. healthcare company focused on developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system (CNS) cancers. The company's lead radiopharmaceutical candidate, rhenium (186Re) obisbemeda, is designed for CNS cancers like glioblastoma (GBM) and leptomeningeal metastases (LM), utilizing localized delivery methods. Its diagnostic subsidiary, CNSide Diagnostics, develops laboratory-developed tests (LDTs) to identify metastatic tumor cells, with its CNSide Test being used in clinical trials and having secured national agreements with major insurers. The company also has a preclinical radiotherapeutic candidate, 188RNL-BAM, for solid organ cancers, particularly liver cancer.
Question:
What are PLUS THERAPEUTICS, INC.'s revenue drivers?
Answer:
Revenue is primarily driven by the development and commercialization of its precision diagnostics and targeted radiopharmaceuticals. The company also receives grant revenue to support its research and development activities.
Cut through noisy SEC filings to find the signal faster
Source-grounded filing intelligence with one-click links back to the filing, so you can move faster and verify everything at the source.
Get Started Free →No credit card required